Selected models (but not limited to):
Our array of services encompasses:
We possess unparalleled expertise regarding the following target tissues/organs:
We employ a variety of experimental methods,
such as:
Contact us for further details regarding our continuously expanding services.
Lunatum Biotech is your reliable and innovative partner for preclinical research and development in the field of molecular musculoskeletal medicine. Our scientists use optimized techniques and work protocols for the isolation and in-depth analysis of on-target and off-target cells. Using a variety of innovative in-vitro modeling systems and in-vivo models, we provide crucial preclinical insights to companies working towards developing targeted drugs for the rapidly expanding orthopedic therapy market.
The disorders listed below provide valuable insight into the numerous unmet treatment needs within musculoskeletal diseases. Please don't hesitate to contact us for in-depth discussions about target diseases, areas of research interests, and how Lunatum Biotech can offer support in developing cures for these conditions. We are deeply committed to collaborating with you to make significant strides in the field of musculoskeletal medicine.
Osteoporosis, Osteogenesis Imperfecta (OI), Fibrous Dysplasia, Hypophosphatasia, Fibrodysplasia Ossificans Progressiva (FOP), Multiple Epiphyseal Dysplasia (MED), Osteonecrosis, bone tumors, bone metastasis, bone fractures, osseous non-unions, bone defects
Let us refine and evaluate your vector, protein, or biomaterial for addressing bone loss arising from trauma, tumor resection, or bone induction for spine fusion. We can evaluate its effectiveness using our extensively documented bone defect model.
References:
- Kunkel, N. A. et al., Comparing the osteogenic potential of bone marrow and tendon-derived stromal cells to repair a critical-sized defect in the rat femur. J Tissue Eng Regen Med, 2017. Jul;11(7): p. 2014-2023
- Betz, V.M. et al.: An expedited approach for sustained delivery of BMP-7 to bone defects using gene activated fragments of subcutaneous fat. J Gene Med, 2016. 18(8):199-207.
- Hoegel, F. S. et al: Bone healing of critical size defects of the rat femur after the application of bone marrow aspirate and two different rh-BMP7 concentrations. Eur J Trauma Emerg Surg, 2015. 41(5): p. 557-63.
- Betz, V.M. et al.: The effect of BMP-7 gene activated muscle tissue implants on the repair of large segmental bone defects. Injury, 2015. 46(12): p. 2351-8.
-Betz, O.B. et al.: Repair of large segmental bone defects: BMP-2 gene activated muscle grafts vs. autologous bone grafting. BMC Biotechnol, 2013. 13: p. 65.
-Betz, O.B.et al.: The repair of critical-sized bone defects using expedited, autologous BMP-2 gene-activated fat implants.Tissue Eng Part A, 2010. 16(3): p. 1093-101.
-Betz, O.B. et al.: Healing of large segmental bone defects induced by expedited bone morphogenetic protein-2 gene-activated, syngeneic muscle grafts. Hum Gene Ther, 2009. 20(12): p. 1589-96
-Betz, O.B.et al.: Delayed administration of adenoviral BMP-2 vector improves the formation of bone in osseous defects.Gene Ther, 2007. 14(13): p. 1039-44.
- Kirker-Head, C. et al.: BMP-silk composite matrices heal critically sized femoral defects. Bone, 2007. 41(2): p. 247-55.
- Betz, V.M. et al.: Healing of segmental bone defects by direct percutaneous gene delivery: effect of vector dose. Hum Gene Ther, 2007. 18(10): p. 907-15.
- Betz, O.B.et al.: Direct percutaneous gene delivery to enhance healing of segmental bone defects. J Bone Joint Surg Am, 2006. 88(2): p. 355-65.
- Meinel, L. et al.: Silk based biomaterials to heal critical sized femur defects. Bone, 2006. 39(4): p. 922-31.
Osteoarthritis, cartilage defects, osteochondral defects, Diastrophic Dysplasia
Tendon ruptures, Tendinitis, chronic tendon degeneration, ligament tears
Osteoarthritis, Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
Sarcopenia, Duchenne Muscular Dystrophy, Myasthenia Gravis, Spinal Muscular Atrophy, Polymyalgia Rheumatica, Polymyositis, muscle injuries
Intervertebral Disc Disease
The above listed disorders are just a few examples to show the significance of musculoskeletal medicine. Contact us for further discussions about target diseases and scientific fields of interest.
Chief Executive Officer and founder; post-doctoral training and Instructor at Harvard Medical School; Head of Orthopedic Regenerative Medicine at the University of Munich LMU; Visiting Scientist at MIT; 25 + years of experience in musculoskeletal gene medicine.
Medical Director and co-founder; post-doctoral training at Harvard Medical School; Orthopedic Surgeon; 20 + years of experience in orthopedic gene therapy.
Chief Scientific Officer ; post-doctoral training at Harvard Medical School; Assistant Professor at Einstein College of Medicine; 25 + years of experience in molecular musculoskeletal medicine.
Please send us a message or call us!
Lunatum Biotech´s phone number:
(+1) 781 518 8894
Lunatum Biotech´s Email:
Lunatum Biotech´s address:
100 Cummings Center, Suite 451C
Beverly, MA 01915
USA